No Data
Eocan Vision Biotech-B (01477.HK): The enrollment of patients for the second Phase III clinical trial of OT-301 in china has been completed.
On December 3, in a report by Gelonghui, Eucanvis Bioscience-B (01477.HK) announced that one of the group's main candidate drugs, OT-301 (NCX470), which is co-developed with Nicox S.A. ("Nicox"), has recently completed its second Phase III clinical trial (the "Denali trial") with over 140 patients enrolled in China. The first Phase III clinical trial of NCX 470 (i.e. the Mont Blanc trial) started in June 2020.
Hong Kong stock fluctuation | Eucon Gravis Biotech-B (01477) rose more than 4% in the afternoon, completion of OT-301 Phase III clinical trial Denali trial with global patient enrollment.
Ocumension Therapeutics (01477) surged over 4% in the afternoon, as of the time of publication, up 3.69% to HKD 5.34, with a turnover of 5.783 million Hong Kong dollars.
Ocumension Therapeutics Enrolls Patients for Second Phase 3 Trial of Glaucoma Drug
Repurchase collection on December 2nd | Tencent, AIA and other companies have successively repurchased, with Tencent spending HKD 0.701 billion.
According to the document disclosed by hkex on December 3, $tencent (00700.HK)$, $aia (01299.HK)$ and others repurchased shares. ① $tencent (00700.HK)$ repurchased 1.76 million ordinary shares on December 2, involving an amount of 0.701 billion HKD, with a repurchase price ranging from 401.2 HKD to 395.6 HKD per share. Since the repurchase authorization resolution, the total number of securities repurchased has reached 0.199 billion shares, accounting for 2.11% of the total issued shares at the time the ordinary resolution was passed. ② $aia (01299.HK)$ repurchased on December
Eukon Vision Biotech-B (01477.HK) repurchased 1,500 shares on December 2.
Globe News reported on December 2 that E.B. Oculomed (01477.HK) announced the repurchase of 1,500 shares, costing HKD 7,820 on December 2.
Buyback collection on November 29 | Tencent, AIA and others repurchase shares, with Tencent spending 0.7 billion Hong Kong dollars.
According to a document disclosed by hkex on December 2, $tencent (00700.HK)$ and $aia (01299.HK)$ repurchased shares.① $tencent (00700.HK)$ repurchased 1.76 million ordinary shares on November 29, involving an amount of 0.7 billion Hong Kong dollars, with a repurchase price ranging from 402.4 Hong Kong dollars to 395 Hong Kong dollars per share. Since the repurchase authorization resolution, the cumulative number of securities repurchased is 0.197 billion shares, accounting for 2.091% of the number of issued shares at the time the ordinary resolution was passed.② $aia (01299.HK)$ on November 29
